Nasdaq atai.
Company Description. ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive …
Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.Summary Real-Time After-Hours Pre-Market Charts NEWS & ANALYSIS News Press Releases Analyst Research ATAI ATAI REAL TIME ATAI Real-Time Quotes 1D 5D 1M 6M YTD 1Y 5Y MAX Last Five Real-Time...Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...atai ended the second quarter of 2022 with a cash position of $312 million, which combined with committed funding from Hercules loan facility is anticipated to provide cash runway into 2025. Cash ...
If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...
A high-level overview of Atai Life Sciences N.V. (ATAI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Nov 30, 2023 · Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine) Aug. 08: CI Atai Life Sciences N.V., Atai Life Sciences AG Enters into the Second Amendment to Loan and Security Agreement with the Several Banks May. 31: CI Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Atai Life Sciences stock is Buy based on the current 4 buy ratings for ATAI. The average twelve-month price prediction for Atai Life Sciences is $12.80 with a high price target of $20.00 and a low price target of $9.00. Learn more on ATAI's analyst rating ...Atai Capital highlighted stocks like Alphabet Inc. (NASDAQ:GOOG) in the Q3 2023 investor letter. Headquartered in Mountain View, California, Alphabet Inc. …
One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...
With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (ATAI-1.75%) is having a rough go of things lately ...
Shares in Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling back some.The average one-year price target for ATAI Life Sciences N.V. (NASDAQ:ATAI) has been revised to 12.57 / share. This is an increase of 5.04% from the prior estimate of 11.97 dated August 31, 2023. Palm Beach, FL – July 27, 2022 - For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam war and is still the preferred anesthetic in battlefield situations. It can be used to induce a kiNov 14, 2023 · NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... For example, they have invested more money into Cybin (NYSE: CYBN) than they have into larger companies such as GH Research (Nasdaq: GHRS) and atai Life Sciences (Nasdaq: ATAI). Obviously, they expect Cybin to have larger returns.Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...
ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...Here are our picks for the five psychedelic companies to watch in 2022: Atai Life Sciences, Berlin, Germany – listed on NASDAQ (ATAI) since July, 2021 – Market cap $999 million. Atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is also one of the largest shareholders ...atai Impact, the philanthropic program of atai Life Sciences (NASDAQ: ATAI) and the Multidisciplinary Association for Psychedelic Studies (MAPS) recently announced a $500,000 donation from atai ...Oct 2, 2023 · NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release. Apr 28, 2023 · NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...
NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...NEW YORK, Nov. 29, 2021-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has increased its ...
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ...111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed …May 11, 2023 · The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ... Nov 30, 2023 · Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine) Aug. 08: CI Atai Life Sciences N.V., Atai Life Sciences AG Enters into the Second Amendment to Loan and Security Agreement with the Several Banks May. 31: CI Atai Life Sciences (NASDAQ: ATAI) is another clinical-stage biopharmaceutical company that seeks to transform the treatment of mental health conditions using innovative psychedelic-based drugs ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Atai Life Sciences stock is Buy based on the current 4 buy ratings for ATAI. The average twelve-month price prediction for Atai Life Sciences is $12.80 with a high price target of $20.00 and a low price target of $9.00. Learn more on ATAI's analyst rating ...8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ... Stock Price & Overview 3.84K followers $1.07 -0.05 ( -4.46%) 4:00 PM 11/21/23 NASDAQ | $USD | Post-Market: $1.11 +0.04 (+3.74%) 7:59 PM Summary Ratings Financials …
He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...
Download Historical Stock Quotes for Atai Life Sciences N.V. [NASDAQ,ATAI] in a range of formats.
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...Aug 8, 2023 · NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... Jan 9, 2023 · NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ... NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR ...Gainers Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) gained 34.1% to settle at $12.58 on Wednesday. ... Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 31.9% to close at $6.82 on Wednesday.Nov 17, 2023 ... atai Life Sciences N.V. (ATAI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy).ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...On the other hand, atai (NASDAQ:ATAI)’s Phase 1 clinical trial testing atypical opioid receptor modulator KUR-101 towards Opioid Use Disorder treatment has provided mixed results, which seem to ...
Atai Life Sciences’ (NASDAQ: ATAI) stock fell more than 40% after the primary endpoint of a phase 2a clinical trial examining the use of ketamine treatment to treat depression was not met.Lucy Scientific Discovery(NASDAQ:LSDI) Holding Weight: 4.84%; Atai Life Sciences(NASDAQ:ATAI) Holding Weight: 4.71%; PSIL Sector Exposure. PSIL Industry Exposure. Full Holdings Details. Similar ETFs. iShares Future Cloud 5G and Tech ETF NYSEARCA:IDAT; Global X Solar ETF NASDAQ:RAYS;Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated coverage of ATAI Life Sciences N.V. (NASDAQ:ATAI) with a Buy recommendation. Analyst Price Forecast Suggests 605.71% Upside. As ...Instagram:https://instagram. nvda dividentretl trackingnyse hlxhow much is a 1971 half dollar coin worth With a Buy rating, Baader Helvea initiated coverage on ATAI Life Sciences NV (NASDAQ:ATAI). The price target seems to have been set at $21.00 for ATAI Life Sciences. The stock has a 52-week-high ...NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... patek philippe grandmaster chime ref 6300a 010marshallscom Nov 21, 2023 · Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares. Nov 21, 2023 · Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares. why is nvda down 8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently ...Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds.